Free tool
FAERS Monitor: Cleocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050680 or its brand name (Cleocin, Clindamycin Phosphate). Reports on generic versions are filed under their own applications.
Reports
4,923
Serious
2,973
60% of reports
Hospitalization
1,434
Death reported
353
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug hypersensitivity554
- drug ineffective431
- rash366
- diarrhoea320
- nausea281
- off label use263
- pain251
- fatigue245
- pruritus207
- dyspnoea185
- headache173
- pyrexia162
- vomiting157
- condition aggravated151
- anxiety149
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 90 |
| 2006 | 82 |
| 2007 | 23 |
| 2008 | 42 |
| 2009 | 84 |
| 2010 | 184 |
| 2011 | 110 |
| 2012 | 136 |
| 2013 | 188 |
| 2014 | 185 |
| 2015 | 240 |
| 2016 | 401 |
| 2017 | 280 |
| 2018 | 377 |
| 2019 | 366 |
| 2020 | 283 |
| 2021 | 231 |
| 2022 | 318 |
| 2023 | 334 |
| 2024 | 316 |
| 2025 | 336 |
| 2026 | 276 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,236 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug hypersensitivitySignal | 554 | 12.3 | 11.3 | 5,756 |
| rashSignal | 366 | 3.6 | 3.3 | 695 |
| pruritusSignal | 207 | 2.3 | 2.0 | 154 |
| anxietySignal | 149 | 2.2 | 1.9 | 102 |
| condition aggravatedSignal | 151 | 2.1 | 1.8 | 90 |
| diarrhoeaSignal | 320 | 2.1 | 1.9 | 194 |
| pyrexiaSignal | 162 | 2.0 | 1.7 | 81 |
| pain | 251 | 1.7 | 1.5 | 82 |
| nausea | 281 | 1.5 | 1.4 | 51 |
| vomiting | 157 | 1.4 | 1.2 | 20 |
| drug ineffective | 431 | 1.4 | 1.3 | 52 |
| dyspnoea | 185 | 1.4 | 1.2 | 21 |
| fatigue | 245 | 1.3 | 1.2 | 22 |
| off label use | 263 | 1.3 | 1.1 | 17 |
| headache | 173 | 1.2 | 1.0 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.